Hefei Lifeon Pharmaceutical Co., Ltd. (SHE:003020)
China · Delayed Price · Currency is CNY 16.30
-0.62 (-3.66%)
Jun 2, 2026, 3:04 PM CST
SHE:003020 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Jan '25 Jan 1, 2025 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,512 | 1,515 | 1,488 | 1,887 | 2,570 | 2,261 |
Other Revenue | 38.52 | 38.52 | 30.32 | 14.25 | 8.86 | 11.77 |
| 1,551 | 1,554 | 1,518 | 1,901 | 2,579 | 2,273 | |
Revenue Growth (YoY) | 0.36% | 2.33% | -20.11% | -26.31% | 13.46% | 20.01% |
Cost of Revenue | 552.07 | 562.94 | 479.67 | 932.11 | 1,619 | 1,369 |
Gross Profit | 998.6 | 990.86 | 1,039 | 968.68 | 960.28 | 904.36 |
Selling, General & Admin | 727.37 | 723.15 | 772.94 | 659.7 | 675.31 | 650.1 |
Research & Development | 109.7 | 110.4 | 91.58 | 84.96 | 73.8 | 65.86 |
Other Operating Expenses | 29.2 | 21.55 | 19.06 | 14.97 | 15.96 | 16.06 |
Operating Expenses | 865.95 | 856.14 | 886.63 | 762.82 | 765.5 | 731.99 |
Operating Income | 132.64 | 134.72 | 152.19 | 205.85 | 194.78 | 172.36 |
Interest Expense | -2.48 | -2.34 | -1.92 | -1.28 | -0.89 | -1.36 |
Interest & Investment Income | 26.1 | 29.61 | 13.62 | 32.14 | 36.68 | 14.58 |
Currency Exchange Gain (Loss) | -0.06 | -0.06 | 0.01 | 0.04 | 0.4 | -0.18 |
Other Non Operating Income (Expenses) | -0.47 | 0.04 | -0.75 | 0.92 | -0.17 | -0.34 |
EBT Excluding Unusual Items | 155.74 | 161.97 | 163.16 | 237.67 | 230.81 | 185.06 |
Gain (Loss) on Sale of Investments | -0.47 | 0.15 | 1.6 | 0.32 | -0.04 | -0.01 |
Gain (Loss) on Sale of Assets | -0 | -0 | 0.02 | - | -2.54 | -0.03 |
Asset Writedown | 1.27 | -0.68 | -6.43 | -0.12 | -0.39 | -0.27 |
Other Unusual Items | 22.39 | 20.36 | 13.46 | 19.55 | 11.98 | 10.09 |
Pretax Income | 178.94 | 181.8 | 171.82 | 257.42 | 239.82 | 194.84 |
Income Tax Expense | 19.4 | 18.24 | 19.34 | 23.53 | 30.57 | 22.61 |
Earnings From Continuing Operations | 159.53 | 163.55 | 152.48 | 233.88 | 209.25 | 172.23 |
Minority Interest in Earnings | 2.7 | 1.64 | 8.12 | -7.21 | - | - |
Net Income | 162.24 | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 |
Net Income to Common | 162.24 | 165.2 | 160.6 | 226.67 | 209.25 | 172.23 |
Net Income Growth | -3.70% | 2.86% | -29.15% | 8.33% | 21.50% | 27.47% |
Shares Outstanding (Basic) | 226 | 228 | 229 | 231 | 227 | 225 |
Shares Outstanding (Diluted) | 226 | 228 | 229 | 231 | 227 | 225 |
Shares Change (YoY) | -1.57% | -0.68% | -0.48% | 1.75% | 0.49% | 33.02% |
EPS (Basic) | 0.72 | 0.72 | 0.70 | 0.98 | 0.92 | 0.76 |
EPS (Diluted) | 0.72 | 0.72 | 0.70 | 0.98 | 0.92 | 0.76 |
EPS Growth | -2.17% | 3.57% | -28.81% | 6.46% | 20.91% | -4.18% |
Free Cash Flow | 127 | 94.43 | 43.05 | 6.14 | -45.79 | -28.24 |
Free Cash Flow Per Share | 0.56 | 0.41 | 0.19 | 0.03 | -0.20 | -0.13 |
Dividend Per Share | 0.417 | 0.417 | 0.417 | 0.347 | 0.267 | 0.288 |
Dividend Growth | - | - | 19.98% | 30.03% | -7.13% | 39.95% |
Gross Margin | 64.40% | 63.77% | 68.41% | 50.96% | 37.23% | 39.78% |
Operating Margin | 8.55% | 8.67% | 10.02% | 10.83% | 7.55% | 7.58% |
Profit Margin | 10.46% | 10.63% | 10.58% | 11.92% | 8.11% | 7.58% |
Free Cash Flow Margin | 8.19% | 6.08% | 2.83% | 0.32% | -1.77% | -1.24% |
EBITDA | 218.61 | 218.59 | 227.68 | 241.56 | 220.72 | 199.92 |
EBITDA Margin | 14.10% | 14.07% | 14.99% | 12.71% | 8.56% | 8.79% |
D&A For EBITDA | 85.96 | 83.87 | 75.49 | 35.71 | 25.94 | 27.55 |
EBIT | 132.64 | 134.72 | 152.19 | 205.85 | 194.78 | 172.36 |
EBIT Margin | 8.55% | 8.67% | 10.02% | 10.83% | 7.55% | 7.58% |
Effective Tax Rate | 10.84% | 10.04% | 11.25% | 9.14% | 12.75% | 11.60% |
Revenue as Reported | 1,551 | 1,554 | 1,518 | 1,901 | 2,579 | 2,273 |